Literature DB >> 12439703

Successful non-T cell-depleted HLA haplo-identical three-loci mismatched hematopoietic stem cell transplantation from mother to son based on the feto-maternal microchimerism in chronic myelogenous leukemia.

N Ochiai1, C Shimazaki, S Fuchida, A Okano, T Sumikuma, E Ashihara, T Inaba, N Fujita, E Maruya, M Nakagawa.   

Abstract

A 17-year-old male with chronic myelogenous leukemia in blast crisis received a non-T cell-depleted (TCD) HLA haplo-identical three-loci mismatched hematopoietic stem cell transplant (HSCT) from his mother. Long-term feto-maternal microchimerism was detected by nested polymerase chain reaction with sequence-specific primer typing. The post-transplantation prophylaxis against graft-versus-host disease (GVHD) was tacrolimus with minidose methotrexate. Sustained engraftment was obtained. Acute GVHD (grade 2) developed, but improved rapidly. Bone marrow aspiration on day 120 showed complete remission. Non-TCD HLA haplo-identical HSCT based on feto-maternal microchimerism might be feasible and has important implications in the selection of alternative family donors in HSCT.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12439703     DOI： 10.1038/sj.bmt.1703736

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  6 in total

1.  Long-term feto-maternal microchimerism revisited: Microchimerism and tolerance in hematopoietic stem cell transplantation.

Authors:  Tatsuo Ichinohe
Journal:  Chimerism       Date:  2010 Jul-Sep

2.  Philadelphia chromosome-positive acute lymphoblastic leukemia rescued with a second allogeneic stem cell transplantation from a haploidentical mother after relapse following cord blood transplantation.

Authors:  Tatsuyuki Kai; Hideo Kimura; Yutaka Shiga; Shin Mineishi; Satoshi Yoshihara; Hiroyasu Ogawa; Etsuko Maruya; Hiroh Saji; Hitoshi Ohto; Yukio Maruyama
Journal:  Int J Hematol       Date:  2004-12       Impact factor: 2.490

3.  Unmanipulated HLA-haploidentical bone marrow transplantation for the treatment of fatal, nonmalignant diseases in children and adolescents.

Authors:  Hiromasa Yabe; Hiroyasu Inoue; Masae Matsumoto; Satoshi Hamanoue; Aiko Hiroi; Takashi Koike; Masahiro Sako; Mitsuhiro Fujiwara; Yasunori Ueda; Etsuko Maruya; Hiroh Saji; Shunichi Kato; Miharu Yabe
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

4.  Outcome of non-T-cell-depleted HLA-haploidentical hematopoietic stem cell transplantation from family donors in children and adolescents.

Authors:  Takao Yoshihara; Keiko Okada; Michihiro Kobayashi; Atsushi Kikuta; Koji Kato; Naoto Adachi; Akira Kikuchi; Hiroyuki Ishida; Yasuzou Hirota; Hiroshi Kuroda; Yoshihisa Nagatoshi; Takeshi Inukai; Kazutoshi Koike; Hisato Kigasawa; Hiroshi Yagasaki; Kiriko Tokuda; Tomoko Kishimoto; Takahide Nakano; Naoto Fujita; Hiroaki Goto; Yozo Nakazawa; Hirokazu Kanegane; Akinobu Matsuzaki; Yuko Osugi; Daiichiro Hasegawa; Nobuhiko Uoshima; Kazuhiro Nakamura; Masahiro Tsuchida; Ryuhei Tanaka; Arata Watanabe; Hiromasa Yabe
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

5.  Successful reduced-intensity stem cell transplantation from an HLA haploidentical 3-loci-mismatched donor on the basis of fetomaternal microchimerism in a patient with advanced acute myeloid leukemia.

Authors:  Nobuhiko Uoshima; Yuri Kamitsuji; Etsuko Maruya; Hiroh Saji
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

Review 6.  How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?

Authors:  Ying-Jun Chang; Leo Luznik; Ephraim J Fuchs; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2016-04-12       Impact factor: 17.388
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.